Jardiance Cost in Florida 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Florida in 2026?

The manufacturer list price for Jardiance sits at approximately $680 per month in Florida for 2026, consistent with national pricing set by Boehringer Ingelheim and Eli Lilly. Without insurance or a savings program, that figure is what most Florida retail pharmacies will quote at the counter. Grocery-chain and big-box pharmacies in the state cluster within a few dollars of that number.

Cash-pay prices at GoodRx-affiliated Florida pharmacies have ranged from roughly $530 to $670 per month depending on ZIP code and which coupon is applied, though GoodRx coupons typically cannot be combined with insurance or the manufacturer savings card. The FDA-approved label lists empagliflozin as a once-daily oral tablet at 10 mg or 25 mg [1]. Both strengths carry the same retail price per tablet, so the monthly cost does not change between doses.

Price transparency tools from the Centers for Medicare and Medicaid Services note that brand-name SGLT2 inhibitors remain among the highest-cost oral antidiabetic agents when paid out of pocket [2]. Florida has no state-level prescription price cap law that applies to Jardiance specifically, so patients bear the full list price unless a payer or program intervenes.

A 90-day supply (roughly $2,040 at list) purchased at a Florida mail-order pharmacy affiliated with a PBM sometimes runs 10 to 15% lower per tablet than a 30-day retail fill, but the absolute dollar difference does not overcome the access barrier for uninsured patients.

Does Florida Medicaid Cover Jardiance?

Florida Medicaid does not cover Jardiance for type 2 diabetes as a standalone indication in 2026. The Florida Agency for Health Care Administration (AHCA) Medicaid preferred drug list places empagliflozin as non-preferred or excluded for the glycemic-control indication, meaning prior-authorization requests for T2D alone are routinely denied [3].

The picture changes for cardiorenal indications. EMPA-REG OUTCOME (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin 10 mg or 25 mg versus placebo in patients with established atherosclerotic cardiovascular disease (hazard ratio 0.62; 95% CI 0.49, 0.77; P<0.001) [4]. Following that 2015 NEJM publication, the FDA expanded Jardiance's label to include a cardiovascular death risk-reduction indication [1]. Florida Medicaid managed-care plans may authorize Jardiance when a beneficiary has a documented heart failure or chronic kidney disease diagnosis alongside T2D, provided prior-authorization criteria are met.

The EMPEROR-Reduced trial (N=3,730) further showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (HR 0.75; 95% CI 0.65, 0.86; P<0.001), a finding that has influenced coverage policy for heart failure plans nationally [5]. Florida Medicaid dual-eligible beneficiaries enrolled in Medicare Part D may access Jardiance through Part D formularies rather than the Medicaid PDL, which creates a separate coverage pathway.

Patients who believe they qualify on cardiorenal grounds should request a written prior-authorization from their prescriber and cite the relevant ICD-10 codes (I50.x for heart failure; N18.x for CKD) when submitting to Florida AHCA [3].

Which Commercial Insurance Plans Cover Jardiance in Florida?

Most large commercial carriers operating in Florida place Jardiance on a mid-tier or specialty tier, typically Tier 3 or Tier 4, with co-pays ranging from $50 to over $200 per month depending on plan design. Florida Blue (the dominant BCBS affiliate), Aetna, UnitedHealthcare, Cigna, and Humana all include empagliflozin on formulary for at least one plan type in 2026, but tier placement and prior-authorization requirements differ by product line.

Medicare Part D plans sold in Florida vary widely. The CMS formulary data show that roughly 60% of standalone PDP plans nationally list at least one SGLT2 inhibitor, though the specific drug and tier differ [2]. Florida Medicare Advantage plans from major carriers often include Jardiance at lower cost-sharing for members with heart failure or CKD diagnoses, reflecting the 2021 FDA label expansion following EMPEROR-Reduced [5].

Employer-sponsored plans administered by large Florida employers (health systems, state agencies, universities) frequently place Jardiance on a Tier 3 with a $75, $120 monthly co-pay after deductible. Checking the specific Summary of Benefits and Coverage (SBC) document is the only way to confirm your plan's tier and any step-therapy requirement before filling.

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors for patients with T2D and established ASCVD, heart failure, or CKD regardless of HbA1c, a position that strengthens medical-necessity arguments during the insurance appeals process [6].

How Does the Boehringer Ingelheim and Lilly Savings Card Work in Florida?

The Jardiance Savings Card, issued jointly by Boehringer Ingelheim and Eli Lilly, is available to commercially insured Florida patients and can reduce out-of-pocket cost to as low as $10 per 30-day fill. Florida patients who are uninsured are not eligible for the standard savings card but may qualify for the patient-assistance program (see below).

Eligibility rules as of 2026 require that the patient have commercial insurance (no government-funded plans, including Florida Medicaid or Medicare), be a U.S. resident, and receive Jardiance for an FDA-approved indication [1]. The card is activated online or by phone through the Lilly/BI joint portal, and the discount is applied at the pharmacy point of sale.

The savings-card program caps annual savings, and the specific cap has been adjusted in prior years. Florida patients should read the current terms at enrollment because the cap resets each January 1. Patients who exhaust the annual cap mid-year revert to their plan's standard co-pay for the remainder of the benefit year.

For uninsured Florida patients with household income at or below 400% of the federal poverty level, Lilly's Insulin Value Program and Boehringer Ingelheim's Cares Foundation Patient Assistance Program may provide Jardiance at no cost. Applications require proof of income and a completed prescriber attestation form.

Is Compounded Empagliflozin Legal in Florida?

Compounded empagliflozin prepared by a Florida-licensed 503A pharmacy is legal in Florida in 2026, provided the compounding pharmacy complies with Florida Board of Pharmacy rules and the federal Food, Drug, and Cosmetic Act's compounding provisions [7]. Florida Statute 465 governs pharmacy practice, and the Florida Board of Pharmacy enforces compliance through inspection and licensure.

A 503A pharmacy compounds for individual patients on a prescription-by-prescription basis and is not permitted to produce large stock batches for resale, a distinction that separates it from a 503B outsourcing facility [7]. For compounded empagliflozin to be dispensed legally, the prescriber must write a patient-specific prescription, the pharmacy must source pharmaceutical-grade API from an FDA-registered supplier, and the compound must not be a copy of a commercially available product without a documented patient-specific reason.

The FDA has not placed empagliflozin on its list of bulk drug substances that may not be used in 503A compounding as of this writing [8]. That status can change, so prescribers and pharmacies should verify current FDA bulk-substance status before initiating compounded empagliflozin therapy.

The HealthRX clinical team uses the following decision framework for Florida patients considering compounded empagliflozin:

1. Confirm the patient has a valid FDA-approved indication (T2D, HFrEF, or CKD with albuminuria).
2. Verify that the compounding pharmacy holds an active Florida 503A license (searchable at the Florida Department of Health MQA licensing portal).
3. Request a Certificate of Analysis from the pharmacy confirming API purity and sterility if applicable.
4. Document the medical necessity for compounding (cost barrier, allergy to excipient, etc.) in the chart.
5. Re-evaluate at 90 days with HbA1c, eGFR, and UACR to confirm therapeutic equivalence.

Cost for compounded empagliflozin from Florida 503A pharmacies is substantially lower than the branded list price, though it varies by pharmacy and formulation. Patients should compare pharmacies because pricing is not standardized.

What Are the Cheapest Ways to Get Jardiance in Florida?

Several pathways can reduce the effective out-of-pocket cost for Florida patients, ranked here roughly from lowest to highest residual cost.

Patient assistance programs (PAP) from Boehringer Ingelheim or Lilly can deliver Jardiance at $0 for qualifying uninsured or underinsured patients. Applications are processed through NeedyMeds or directly through the manufacturer portal [9].

Compounded empagliflozin from a licensed Florida 503A pharmacy is typically the lowest-cost option for patients who do not qualify for PAP but cannot afford the brand.

The BI/Lilly savings card reduces cost to $10 per month for commercially insured patients. This is the most accessible pathway for working-age Florida adults with employer-sponsored coverage.

GoodRx and similar discount platforms negotiate rates with Florida retail pharmacies and can bring the cash price down by 15 to 25% from list, though not to the levels achievable through PAP or compounding.

Medicare Extra Help (Low Income Subsidy) for dual-eligible Florida patients can sharply reduce Part D cost-sharing for Jardiance when it appears on the plan formulary [2].

The ADA's 2024 Standards of Care explicitly state: "Cost is a major barrier to medication adherence, and clinicians should proactively discuss cost with patients and identify less expensive alternatives when possible" [6]. Florida clinicians are encouraged to document this conversation in the medical record.

Why Does Cost Matter Clinically for Empagliflozin?

Adherence to empagliflozin directly affects outcomes. EMPA-REG OUTCOME enrolled 7,020 patients with T2D and established ASCVD and showed that the number needed to treat to prevent one cardiovascular death over 3.1 years was 39 [4]. Patients who discontinue therapy due to cost forfeit that benefit.

A 2023 JAMA Internal Medicine analysis found that cost-related medication non-adherence affected approximately 29% of U.S. adults with diabetes in the prior 12 months, with lower-income patients disproportionately affected [10]. Florida has one of the highest proportions of uninsured non-elderly adults in the nation at roughly 11% as of 2023, per CDC estimates [11], making cost a clinically meaningful access barrier in this state specifically.

Beyond glycemic control, empagliflozin's cardiorenal benefits are captured only with sustained use. EMPA-KIDNEY (N=6,609) showed a 28% reduction in the composite of kidney disease progression or cardiovascular death with empagliflozin versus placebo (HR 0.72; 95% CI 0.64, 0.82; P<0.001) in patients with CKD, many of whom had eGFR as low as 20 mL/min/1.73 m² [12]. Interrupting therapy eliminates this protection.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for type 2 diabetes states: "SGLT2 inhibitors with proven cardiovascular benefit are recommended for patients with T2D and established cardiovascular disease or high cardiovascular risk, independent of baseline HbA1c or current glucose-lowering therapy" [13].

Can I Get a Jardiance Prescription via Telehealth in Florida?

Florida law permits telehealth prescribing of Jardiance by licensed Florida prescribers. The Florida Telehealth Act (Section 456.47, Florida Statutes) allows physicians, advanced practice registered nurses, and physician assistants to establish a patient-physician relationship and prescribe Schedule V and non-scheduled medications via synchronous audio-video encounters [14].

Empagliflozin is not a controlled substance, so DEA telehealth rules that restrict Schedule II-IV prescribing do not apply. A Florida-licensed telehealth provider can order Jardiance after reviewing labs (at minimum a recent basic metabolic panel to assess eGFR and potassium) and taking a medication history. Because empagliflozin is contraindicated in patients with eGFR <20 mL/min/1.73 m², lab review before prescribing is not optional, even via telehealth [1].

HealthRX Florida-licensed clinicians routinely complete the following workflow for new telehealth Jardiance starts: (1) review uploaded labs no older than 90 days; (2) confirm no active genital mycotic infection (a contraindication precaution); (3) start at 10 mg once daily with morning administration preferred; (4) schedule a 4-week follow-up for eGFR and symptom check; and (5) escalate to 25 mg at the T2D glycemic-control visit if tolerated and indicated.

Empagliflozin Safety: Key Points Florida Patients Should Know

The FDA prescribing information for Jardiance includes a boxed warning for urinary tract and genital mycotic infections, and clinicians should counsel Florida patients about hydration given the state's heat and humidity [1]. Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious adverse event; patients on ketogenic diets or fasting protocols should discuss this risk with their prescriber [8].

Volume depletion is a concern in patients taking loop diuretics concurrently. The DAPA-HF and EMPEROR-Reduced trials both prespecified diuretic co-administration analyses and found SGLT2 inhibitors well tolerated, but individual Florida patients on high-dose furosemide for heart failure deserve closer monitoring of creatinine and electrolytes at 2 and 4 weeks after initiation [5].

The FDA's 2023 label update clarified that empagliflozin may be used down to eGFR 20 mL/min/1.73 m² for cardiorenal indications, expanding access for Florida's large CKD population [1]. Below eGFR 20, the drug should not be initiated, though it need not be stopped in patients who reach that threshold while already on therapy, per prescribing-information language.

Patients should be counseled to hold empagliflozin 3 to 4 days before any surgical procedure or prolonged fasting to reduce euDKA risk, consistent with guidance from the American Diabetes Association and the Society for Ambulatory Anesthesia [6].